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Objective: The Talent endovascular graft has been used in the treatment of abdominal aortic aneurysms (AAAs) in more
than 13,000 patients worldwide. However, information regarding the results of its use has been limited. This report
describes the experience with 368 patients with AAAs who underwent treatment at four medical centers as part of an
investigator-sponsored investigational device exemption trial.
Methods: Patients with AAAs were enrolled at four sites during a 32-month period from January 1999 to July 2001. All
patients underwent treatment for infrarenal AAA with the Talent endovascular graft. Repair was performed with
transrenal stent fixation under epidural (362/368 patients; 98.3%), local (4/368 patients; 1.1%), or general (2/368
patients; 0.5%) anesthesia. The average diameters were: maximum aortic aneurysm, 6.2 1.2 cm; proximal aortic fixation
site, 2.6  0.4 cm; and distal iliac fixation site, 1.4  0.6 cm. Bifurcated grafts were used in 276 of 366 patients (75%),
aortouniiliac in 57 of 366 patients (16%), and tube aortoaortic in 33 of 366 patients (9%). Multiple comorbid medical
conditions were present in all patients (average, 4.7 conditions/patient). The mean age was 75.8 years, and 85% of the
patients were male. Follow-up period ranged from 2 to 33 months (mean, 7.3 months).
Results: Endovascular graft deployment was accomplished in 366 of 368 patients. In the 263 patients followed for at least
6 months after endovascular repair, AAA diameter decreased by 5 mm or more in 83 patients (32%); diameter remained
unchanged (change < 5 mm) in 157 patients (60%) and increased by 5 mm or more in 23 patients (8.7%). Major
morbidity occurred in 46 of 368 patients (12.5%), and minor morbidity occurred in 31 of 368 (8.4%). The 30-day
mortality rate was 1.9%. Secondary procedures were performed in 32 patients (8.7%). Late rupture occurred in two
patients, and late deaths unrelated to AAA occurred in 32 patients (8.7%) during the follow-up period. The primary
technical success rate for all patients was 93.4%. The 30-day primary procedural success rate was 73.3%. The 30-day
secondary procedural success rate was significantly higher at 85.8%. Computed tomographic scan was performed within
1 month after surgery in 349 patients. An endoleak was present in 43 of 349 patients (12.3%). These endoleaks were
comprised of 10 attachment site (type I; 2.9%), 31 retrograde side-branch (type II; 8.9%), and two transgraft (type III;
0.6%).
Conclusion: These midterm findings show a high degree of technical and procedural success achieved in a patient
population with extensive comorbid medical illnesses with low perioperative morbidity and mortality rates. Further
follow-up study will be necessary to determine the effectiveness of the Talent endograft for the long-term treatment of
AAA. (J Vasc Surg 2002;35:1123-8.)
In the 10 years since the first published report of
endovascular repair of abdominal aortic aneurysms (AAA),1
the devices used for endovascular repair have gone through
several phases of evolution. Physician-fabricated stent grafts
have been largely replaced with commercially produced
endovascular grafts.2-6 Extensive data have been published
on the results of AAA repair with the first generation of
commercially produced devices, including the EVT/
Guidant Ancure (Menlo Park, Calif)7,8 and the Medtronic
AneuRx (Minneapolis, Minn) grafts.9 Modifications to the
original design concepts of these devices have resulted in
subsequent generations of additional endovascular grafts
that are undergoing clinical evaluation.10,11 The Talent
endovascular device (Medtronic/AVE-Worldmedical,
Sunrise, Fla) is currently being evaluated in a phase II Food
and Drug Administration trial to determine its efficacy in
the treatment of AAA.12 The device, with both the original
and the modified low-profile delivery systems, has been
used in AAA repair in more than 13,000 patients world-
wide, making it one of the most widely used endovascular
grafts to date. Despite this extensive clinical experience,
limited data regarding the results of AAA treatment with
the Talent low-profile system (Talent-LPS) graft have been
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published.13-17 This report details the results of a multi-
center investigational device exemption trial in which 368
patients with AAA underwent treatment with the Talent-
LPS endovascular graft system.
PATIENTS AND METHODS
Database and patient demographics. From January
1999 to July 2001, a consecutive series of 368 patients with
AAA were enrolled in a multicenter investigational device
exemption trial with the Talent-LPS endovascular grafting
system. All data regarding each patient, procedure, and
follow-up study were entered prospectively in a computer-
ized vascular registry. All procedures were performed with
protocol approved by the Institutional Review Board of the
Mount Sinai School of Medicine and approved for an
investigational device exemption by the Food and Drug
Administration. The responsible authors had access to the
raw data, which was reviewed to confirm the statistical
analysis before writing the manuscript. All patients had
extensive concomitant medical conditions that rendered
conventional open surgical repair high risk (average, 4.7
comorbid conditions/patient; Table I).
Endovascular device description. The Talent-LPS
endovascular grafting system has been described in detail
previously.12 Briefly, the endoprosthesis is comprised of
woven polyester fabric, which is supported along its entire
length with self-expanding nitinol stents joined by a nitinol
spine (Fig 1). A 15-mm uncovered proximal stent allows
for transrenal fixation (Fig 2). The endoprosthesis is mod-
ular and is custom fabricated to the specifications of each
individual patient anatomy. The endoprosthesis may be
made in a bifurcated aortobiiliac, a tapered aortouniiliac, or
a tube aortoaortic configuration. The diameters available
for the aortic body of the device range between 16 and 36
mm. The iliac limbs range from 8 to 22 mm in diameter.
The delivery system used to deploy the Talent endopros-
thesis contains an internal push rod placed coaxially within
a tapered-tipped delivery sheath. The outer diameter of the
delivery system ranges between 18F and 24F. Exchange of
the delivery sheath over the push rod exposes the endopros-
thesis, allowing self-expansion and deployment. A compli-
ant polyurethane balloon is used to ensure complete appo-
sition of the endoprosthesis to the artery wall.
Preoperative management. Preoperative assessment
included standard contrast arteriography and helical com-
puted tomographic (CT) scan, with intravenous contrast
and images acquired at 3-mm intervals. These studies were
used to determine suitability for endovascular repair and to
prepare the specifications of the endovascular graft. Maxi-
mum aortic diameter ranged from 5.1 cm to 10.2 cm
(mean, 6.2  1.2 cm). The average maximum common
iliac artery diameter was 15.1 4.5 (range, 0.8 to 6.0 cm).
The average diameter of the aorta at the proximal implan-
tation site was 2.6  0.4 cm (range, 1.8 to 3.4 cm). The
diameter of the iliac arteries at the distal implantation site
ranged from 0.6 to 2.2 cm (mean, 1.4  0.6 cm).
Surgical procedure. All procedures were carried out
in the operating room with a radiolucent table under
fluoroscopic guidance. Epidural or spinal anesthesia was
used in 362 of 368 patients (98.3%). General anesthesia was
used in four cases (1.1%), and local anesthesia in two cases
(0.5%). Exposure of the common femoral and distal exter-
nal iliac arteries was performed with an oblique groin
incision.18 Bifurcated aortobiiliac endoprostheses were
used in 276 of 366 patients (75.4%) (Fig 3); tapered
aortouniiliac endoprostheses were placed in conjunction
with concomitant femorofemoral bypass and contralateral
common iliac artery occlusion in 57 patients (15.6%), and
tube aortoaortic endoprostheses were used in 33 patients
(9.0%). All patients were admitted to the hospital after
surgery for observation, and 87% were discharged to home
on the 1st postoperative day.
Postoperative monitoring and follow-up examina-
tion. All patients were entered into a standard follow-up
protocol that included office visits within 1 month of
surgery, at 6 and 12 months after surgery, and annually
thereafter. During the visit, a detailed history and physical
examination were performed. Plane radiographs of the
abdomen and a contrast enhanced helical CT scan also were
obtained at these intervals. Angiography was performed
selectively on the basis of persistent endoleak or aneurysm
expansion or for evidence of graft limb compromise. Follow-
up periods ranged from 2 to 33 months (mean, 7.3 months).
Definitions and statistical analysis. Definitions used
are those outlined by the Ad Hoc Committee on Reporting
Standards, Society for Vascular Surgery/North American
Chapter of the International Society of Cardiovascular Sur-
gery.19 In addition, the definition of primary technical
success is survival of the procedure with an excluded aneu-
rysm (no endoleak) and a patent graft without need for a
second intervention as described by Zarins et al.20 Primary
procedural success was defined as survival at 30 days with a
patent graft, an excluded aneurysm, no need for reopera-
tion or secondary procedures, and no major complication.
Secondary procedural success included survival at 30 days
with a patent graft and an excluded aneurysm.20 All figures
are represented as the mean  the standard deviation. A
Table I. Patient demographics and comorbid illnesses
Characteristic No.
Male gender 313 (85%)
Hypertension 254 (69%)
Coronary artery disease 217 (59%)
Previous CABG or PTCA 88 (24%)
COPD 92 (25%)
Hypercholesterolemia 66 (18%)
Renal insufficiency 48 (13%)
End stage renal disease 7 (2%)
Peripheral vascular disease 48 (13%)
Diabetes 37 (10%)
Stroke or TIA 18 (5%)
History of recent smoking 309 (84%)
Average age (years) 75.8
CABG, Coronary artery bypass grafting; PTCA, percutaneous transluminal
angioplasty; COPD, chronic obstructive pulmonary disease; TIA, transient
ischemic attack.
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Student t test was used to compare continuous variables.
Significance was assumed at a P value of less than .05.
RESULTS
Procedural and technical success. The Talent endo-
vascular graft was deployed in 366 of the 368 patients enrolled
in the study. The primary technical success rate for all patients
was 93.4%. The 30-day primary procedural success rate was
73.3%. The 30-day secondary procedural success rate was
significantly higher as expected and was 85.8%.
Aneurysm size. Aneurysm size was calculated for pa-
tients with 6 months or more of follow-up examination.
Maximum aortic diameter decreased by 5 mm or more in
83 of 263 patients (32%). Maximum aortic diameter re-
mained unchanged (change  5 mm) in 157 of 263 pa-
tients (60%). Maximum aneurysm size increased by 5 mm
or more in 23 of 263 patients (8.7%). Twenty-three pa-
tients with an increase in aneurysm size had a demonstrable
endoleak on CT scan results. However, no endoleak was
shown in the remaining 10 patients. For the study group
overall, the average maximum aortic diameter consistently
decreased during the follow-up period. A statistically sig-
nificant reduction in average maximum aneurysm size was
shown for the 165 patients who were followed for at least
12 months (mean preoperative aneurysm diameter, 59.7
8.9, versus mean 12-month aneurysm diameter, 55.4 
11.2; P  .014).
Endoleaks. Endoleaks were present in a total of 43 of
349 cases (12.3%) on CT scan results obtained within 30
days after surgery. These endoleaks were comprised of 10
attachment site (type I; 2.9%), 31 retrograde side-branch
(type II; 8.9%), and two transgraft (type III; 0.6%). All
transgraft endoleaks were successfully treated with second-
Fig 2. Uncovered proximal stent (15 mm) allows for transrenal
device fixation.
Fig 1. Talent endovascular prostheses. A, Modular bifurcated prosthesis is comprised of aortic body and ipsilateral
iliac limb and separate contralateral iliac limb. B, Aortouniiliac prosthesis is gradually tapered from aortic attachment
site to iliac attachment site and is used in conjunction with femorofemoral crossover graft and occlusion of contralateral
common iliac artery. C, Aortoaortic tube prosthesis.
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ary endovascular interventions. At 12 months, only eight of
165 patients (4.8%) showed retrograde side-branch en-
doleaks. Attachment site endoleaks persisted in all patients
who were unable to undergo secondary endovascular pro-
cedures or conversion to conventional open surgical repair
(three patients at 12 months after surgery). Secondary
procedures could not be performed because of inadequate
proximal implantation length distal to the renal ostia. Two
patients with persistent attachment site endoleaks that
could not be treated with endovascular means and who
were unable to undergo conventional open repair died of
subsequent aneurysm rupture at 18 and 23 months, respec-
tively, after surgery.
Secondary procedures. Conversion to open surgical
repair was necessary in four patients with attachment site
endoleaks not amenable to treatment with endovascular
means. One of these four patients died of multisystem
organ failure in the 30-day postoperative period. During
the initial 30-day follow-up period, 10 patients (2.7%) had
iliac limb occlusion. An additional eight patients (2.2%) had
iliac limb occlusion develop during the subsequent fol-
low-up period. Limb occlusion was treated with thrombec-
tomy, angioplasty, and stent placement in six of 18 cases
(33%), with femorofemoral or axillofemoral bypass in 11 of
18 cases (61%), and with no intervention in one patient
(6%). Coil embolization of retrograde side-branch en-
doleaks that persisted for more than 6 months and were
associated with an increase in aneurysm size was performed
in five patients (16% of type II endoleaks).
Morbidity and mortality. The 30-day perioperative
mortality rate was 1.9%(7/368). Causes of death included
myocardial infarction (n  3), arrhythmia (n  1), and
multisystem organ failure (n  3). The total 30-day major
morbidity rate was 12.5% (46/368; Table II), and the total
30-day minor morbidity rate was 8.4% (31/368; Table
III). Late death unrelated to the aneurysm or its repair
occurred in 32 patients (8.7%) during the follow-up period.
DISCUSSION
Endovascular treatments for AAA have undergone con-
siderable evolution with a succession of modifications and
improvements since the earliest physician-made devices
were used.1-13 These changes have allowed a greater num-
ber of patients with a greater range of anatomic variability
to undergo endovascular treatment.13 Results with ad-
vanced generation devices have been reported to be supe-
rior to those achieved with first generation grafts.9,11,21,22
Fig 3. Treatment of AAA with Talent-LPS device. A, Marked tortuosity of proximal aortic neck presented significant
challenge to endovascular treatment. B, Use of proximal extension prosthesis permitted device to conform to aortic
neck and prevent endoleak at proximal fixation site.
Table II. Major morbidity and mortality
Characteristic No.
Systemic Myocardial infarction 11 (3.0%)
Cardiac arrhythmia 1 (0.3%)
Pulmonary failure 4 (1.1%)
Renal failure 3 (0.8%)
Congestive heart failure 3 (0.8%)
Technical Iliac graft limb occlusion 10 (2.7%)
Conversion to open repair 4 (1.1%)
Graft migration 6 (1.6%)
Renal artery occlusion 3 (0.9%)
Graft infection 1 (0.3%)
Total 46 (12.5%)
30-day mortality 7 (1.9%)
Table III. Minor morbidity
Characteristic No.
Hematoma 21 (5.7%)
Lymphocele 8 (2.2%)
Superficial wound infection 2 (0.5%)
Total 31 (8.4%)
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The Talent-LPS endovascular grafting system uses sev-
eral features that may contribute to successful treatment
outcomes for endovascular AAA repair. Custom fabrication
of devices allowed a greater range of anatomic configura-
tions to be treated in this study. The wide array of proximal
neck (1.8 to 3.4 cm) and iliac (0.6 to 2.2 cm) implantation
sizes treated in this study are an indication of the anatomic
flexibility that can be achieved with custom fabrication. The
patient with the 3.4-cm proximal neck had Ehlers-Danlos
syndrome and was at high risk for standard arterial surgery.
The endovascular device can be used in patients not ana-
tomically suitable for treatment with the currently ap-
proved devices. In addition, the use of a 15-mm uncovered
proximal stent allowed for transrenal fixation of the endo-
prosthesis in the patients treated in this study. Transrenal
fixation may allow successful exclusion of a greater propor-
tion of AAAs with short proximal implantation sites as
compared with proximal fixation that is limited to the
infrarenal aorta.23
All patients who underwent treatment in this multi-
center study were at high risk for conventional open surgi-
cal repair on the basis of the number and nature of their
comorbid medical conditions. Population-based studies
have consistently indicated that although mortality rates
less than 5% can be achieved in patients at good risk in
centers of excellence in vascular surgery, mortality rates
increase dramatically when AAA repair is undertaken in
patients with significant concomitant medical diseases.24,25
These patients at high risk were able to undergo endovas-
cular AAA repair with acceptable morbidity and mortality
rates. In addition, the primary goals of treatment, prevention
of aneurysm rupture and aneurysm-related death,26 were suc-
cessfully achieved in more than 98% of patients during short-
term and intermediate-term follow-up periods.
A number of questions regarding the durability of
endovascular repair of AAA remain to be answered. Previ-
ous studies have indicated that endovascular repair is asso-
ciated with an increased incidence of subsequent need for
intervention to preserve aneurysm exclusion as compared
with conventional open repair.20,27 Although some prob-
lems related to device fatigue and failure have been success-
fully addressed with technical improvements,20 the devel-
opment of late complications, such as new endoleaks or
graft limb occlusions, has not been eliminated. Develop-
ment of distal attachment site endoleak may be observed in
aortoaortic tube prostheses, and their use has been aban-
doned for fusiform AAA in the participating centers. The
development of late endoleaks originating from the distal
aortic implantation site in aortoaortic tube grafts can be
eliminated with the preferential use of bifurcated or aortou-
niiliac devices.
Continued radiologic follow-up examination of all pa-
tients with AAA treated with endovascular means remains
mandatory. In addition to assessment of the repair with
regard to endoleaks, aneurysm size determination may be
performed to assess the adequacy of treatment. In this
study, successful treatment was suggested with stabilization
or reduction in AAA size in 91.3% of patients. Aneurysm
diameter increase was most frequently associated with a
new or persistent endoleak and was considered an indica-
tion for further therapy in all cases where such intervention
was possible. Both instances of aneurysm rupture after
endovascular treatment occurred in association with en-
doleaks originating from the proximal implantation site
that could not be treated with endovascular techniques.
The risk of mortality associated with conventional open
repair was considered to be prohibitive in both of these
patients.
In conclusion, the Talent endovascular grafting system
has been used as an effective means for the prevention of
aneurysm rupture in a large number of patients with con-
siderable comorbid medical illnesses. Aneurysm exclusion
was achieved with low perioperative morbidity and mortal-
ity rates. The degree of technical and procedural success
achieved in this difficult-to-treat patient population is com-
parable with that reported for the phase I and II trials of
other endovascular devices. Although the short-term and
intermediate-term results with the Talent endovascular
graft are encouraging, careful continued follow-up study
will be necessary to determine the long-term effectiveness
of this system for the treatment of AAA.
We thank Mr Joseph Samet for assistance in the prep-
aration of the figures for this manuscript.
REFERENCES
1. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft
implantation for abdominal aortic aneurysms. Ann Vasc Surg 1991;5:
491-9.
2. Parodi JC, Marin ML, Veith FJ. Transfemoral, endovascular stented
graft repair of an abdominal aortic aneurysm. Arch Surg 1995;130:549-
52.
3. Marin ML, Veith FJ, Cynamon J, Sanchez LA, Lyon RT, Suggs WD, et
al. Initial experience with transluminally placed endovascular grafts for
the treatment of complex vascular lesions. Ann Surg 1995;222:449-65.
4. Chuter TAM, Risberg B, Hopkinson BR, Wendt G, Scott RA, Walker
PJ, et al. Clinical experience with a bifurcated endovascular graft for
abdominal aortic aneurysm repair. J Vasc Surg 1996;24:655-66.
5. May J, White G, Waugh R, Yu W, Harris J. Treatment of complex
abdominal aortic aneurysms by a combination of endoluminal and
extraluminal aortofemoral grafts. J Vasc Surg 1994;19:824-33.
6. Veith FJ, Ohki T. Newer developments in endovascular graft treatment
for aortic and aortoiliac aneurysms. A seven-year experience. J Cardio-
vasc Surg (Torino) 2000;41:869-70.
7. Moore WS, Rutherford RB. Transfemoral endovascular repair of ab-
dominal aortic aneurysms: results of the North American EVT phase 1
trail. EVT Investigators. J Vasc Surg 1996;23:543-53.
8. Makaroun MS. The Ancure endografting system: an update. J Vasc Surg
2001;33:S129-34.
9. Zarins CK, White RA, Moll FL, Crabtree T, Bloch DA, Hodgson KJ, et
al. The AneuRx stent graft: four-year results and worldwide experience.
J Vasc Surg 2000;33:S135-45.
10. Matsumura JS, Katzen BT, Hollier LH, Dake MD. Update on the
bifurcated Excluder endoprosthesis: phase I results. J Vasc Surg 2001;
33:S150-3.
11. Greenberg RK, Lawrence-Brown M, Bhandari G, Hartley K, Stelter W,
et al. An update of the Zenith endovascular graft for abdominal aortic
aneurysms: initial implantation and mid-term follow-up data. J Vasc
Surg 2001;33:S157-64.
12. Criado FJ, Wilson EP, Fairman RM, Abul-Khoudoud O, Wellons E.
Update on the Talent aortic stent-graft: a preliminary report from
United States phase I and II trails. J Vasc Surg 2001;33:S146-9.
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 6 Faries et al 1127
13. Criado FJ, Fry PD, Machan LS, Twena M, Patten P. The Talent
endoluminal AAA stent-graft system. Report of the phase I USA trial,
and summary of worldwide experience. J Mal Vasc 1998;23:371-3.
14. Velazquez OC, Larson RA, Baum RA, Carpenter JP, Golden MA,
Mitchell ME, et al. Gender-related differences in infrarenal aortic aneu-
rysm morphologic features: issues relevant to Ancure and Talent en-
dografts. J Vasc Surg 2001;33:S77-84.
15. Hausegger KA, Mendel H, Tiessenhausen K, Kaucky M, Aman W, et al.
Endoluminal treatment of infrarenal aortic aneurysms: clinical experi-
ence with the Talent stent-graft system. J Vasc Interv Radiol 1999;10:
267-274.
16. Chavan A, Cohnert TU, Heine J, Dresler C, Leuwer M, Harringer W,
et al. Endoluminal grafting of abdominal aortic aneurysms: experience
with the Talent endoluminal stent graft. Eur Radiol 2000;10:636-41.
17. Criado FJ, Wilson EP, Wellons I, Abul-Khoudoud O, Gnanasekeram
H. Early experience with the Talent stent-graft system for endoluminal
repair of abdominal aortic aneurysms. Tex Heart Inst J 2000;27:128-
35.
18. Caiati JM, Kaplan D, Gitlitz D, Hollier LH, Marin ML. The value of the
oblique groin incision for femoral artery access during endovascular
procedures. Ann Vasc Surg 2000;14:248-53.
19. Ahn SS, Rutherford RB, Becker GJ, Comerota AJ, Johnston KW,
McClean GK, et al. Reporting standards for lower extremity arterial
endovascular procedures. J Vasc Surg 1993;17:1103-7.
20. Zarins CK, White RA, Schwarten K, Kinney E, Diethrich EB, Hodgson
KJ, et al. AneuRx stent graft versus open surgical repair of abdominal
aortic aneurysms: multicenter prospective clinical trial. J Vasc Surg
1999;29:292-308.
21. May J, White G, Waugh R, Stephen MS, Chaufour X, et al. Comparison
of first- and second-generation prostheses for endoluminal repair of
abdominal aortic aneurysms: a 6-year study with life table analysis. J
Vasc Surg 2000;32:124-9.
22. Jacobowitz GR, Lee AM, Riles TS. Immediate and late explantation of
endovascular aortic grafts: the Endovascular Technologies experience. J
Vasc Surg 1999;29:309-16.
23. Marin ML, Parsons RE, Hollier LH, Mitty HA, Ahn J, Parsons RE, et
al. Impact of transrenal aortic endograft placement of endovascular graft
repair of abdominal aortic aneurysms. J Vasc Surg 1998;28:638-46.
24. Veith FJ, Goldsmith J, Leather RP, Hannan EL. The need for quality
assurance in vascular surgery. J Vasc Surg 1991;13:523-6.
25. Katz DJ, Stanley JC, Zelenock GB. Operative mortality rates for intact
and ruptured abdominal aortic aneurysms in Michigan: an eleven-year
statewide experience. J Vasc Surg 1994;19:804-17.
26. Zarins CK, Arko FR, Lee A, Hill BB, Olcott C, et al. Effectiveness of
endovascular versus open repair in prevention of aneurysm related
death. Paper presented at: Fifty-fifth Annual Meeting of the Society for
Vascular Surgery; June 10, 2001; Baltimore, Md.
27. May J, White GH, Waugh R, Ly CN, Stephen MS, Jones MA, et al.
Improved survival after endoluminal repair with second-generation
prosthesis compared with open repair in the treatment of abdominal
aortic aneurysms: a 5-year concurrent comparison using life table
method. J Vasc Surg 2001;33:S21-6.
Submitted Sep 13, 2001; accepted Dec 10, 2001.
DISCUSSION
Dr Frank LoGerfo (Boston, Mass). Peter, maybe you could
explain the process here in terms of an investigational device and
where this device is in that evolution. I assume your mortality rate
here was zero.
Dr Peter Faries. Actually, 1.9% was the 30-day mortality
rate. The Talent device had been used extensively in Europe,
and the majority of their experience has taken place in those
centers. It has only more recently begun the Food and Drug
Administration phase 1 and 2 trials for approval for use in the
United States. This trial was conducted as part of an investiga-
tional device exemption for high-risk patients who were consid-
ered to be at prohibitive risk or increased risk for standard
aneurysm surgery and as such is an investigator-sponsored trial,
distinct from the phase 2 trial.
Dr Gregorio Sicard (St Louis, Mo). In your review, did you
see any problem with proximal endograft migration?
Dr Faries. We have only seen migration in 1% of patients,
and that seems to be related to either inappropriate selection of a
too short proximal neck or inaccurate placement of the proximal
fixation site. In patients who have had an adequate length 1.5 cm
of proximal aortic neck and in whom the graft is deployed in an
accurate position, we have not seen significant problems with
migration.
Dr David Brewster (Boston, Mass). Peter, you had nice early
results, which as you indicated are similar to the short-term results
of many other series. What was your mean duration of follow-up?
You seem to be implying midterm results, but are you in fact at
midterm in terms of follow-up? And secondly, the Talent device
has often been used by investigators for challenging anatomy that
falls outside of the boundaries of other clinical trial protocols. What
were your selection criteria? Were you in fact treating big necks
over 28 mm, etc?
Dr Faries. With regard to the second question, a number of
these patients did have what you describe as challenging anatomy,
certainly anatomy that could not be treated with the commercially
available devices currently. We did have a significant proportion of
patients whose necks were over 28 mm, and the graft itself is
produced up to 36 mm in its proximal diameter. We oversize by
about 4 mm typically, so we have treated patients up to 32 mm
with the device itself.
The average follow-up was 7.3 months for these patients. The
longest follow-up in this group was 33 months. Whether that
constitutes midterm or not is difficult to say. We felt that it did and
described it as that, but I am not sure that what actually defines a
midterm follow-up is well-defined.
Dr Joseph Meyer (Concord, NH). I enjoyed your paper
very much. I am wondering how you excluded a graft complication
as a cause of death in the 10% of people that died after follow-up,
particularly if postmortem examination was not performed.
Dr Faries. Typically all patients have been followed carefully,
and those who have died in follow-up have had their complete
medical record acquired from the institution where they were
treated. Those determinations were made by autopsy when possi-
ble, and when not possible, it is typically apparent what the cause of
death was.
Dr Robert Zwolak (Lebanon, NH). Peter, very nice paper.
I was curious about the 4% 30-day and the 1% 12-month type 1
endoleak. Does that imply a more permissive approach towards
type 1 endoleaks, or are these simply patients that are too sick or
refusing subsequent intervention?
Dr Faries. If I understand your question correctly, you are
asking why was there still 1% endoleak at 12 months? Typically,
those are patients in whom the anatomy simply does not permit
placement of an extension proximal cuff. They have a very short
neck and were not considered to be candidates for open surgical
repair. These patients were particularly poorly off physiologically
and were thought to be prohibitively risky to convert to open
repair. So that explains the persistence of type 1 endoleaks at 12
months.
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